The FibroCAN study is focused on understanding the effects of a medication called Finerenone on a condition known as diabetic cardiovascular autonomic neuropathy, which affects people with type 2 diabetes. This condition involves damage to the nerves that control the heart and blood vessels, leading to issues with heart function. The study will explore how Finerenone, a type of medication known as a mineralocorticoid receptor antagonist, might help modify the disease in its early stages.

The purpose of the study is to investigate the potential benefits of Finerenone in improving nerve function, reducing fibrosis (a process where tissues become thickened and scarred), and decreasing inflammation in the body. Participants will be randomly assigned to receive either Finerenone or a placebo, and neither the participants nor the researchers will know who is receiving which treatment. This approach is known as a double-blind study, which helps ensure the results are unbiased.

The study will last for 78 weeks, during which participants will undergo various tests to assess nerve function, heart health, and levels of fibrosis and inflammation. These tests will help researchers understand how Finerenone affects the body and whether it can provide benefits for people with early-stage diabetic cardiovascular autonomic neuropathy. The findings from this study could lead to better treatment options for managing this condition in the future.